Advertisement
Drug Discovery
Subscribe to Drug Discovery

The Lead

EMD Serono Announces 2014 GMSI Grant Winners

September 15, 2014 11:29 am | News | Comments

EMD Serono announced the recipients of the second annual Grant for Multiple Sclerosis Innovation at the 2014 Joint ACTRIMS-ECTRIMS Meeting of the Americas Committee for Treatment and Research in MS (ACTRIMS) and European Committee for Treatment and Research in MS (ECTRIMS). Read more...

Akashi Acquires Global Rights to Novel DMD Treatment

September 15, 2014 11:16 am | News | Comments

Akashi Therapeutics Inc. announced that it has...

NIH Awards Aim to Improve Understanding of Cell Pathways

September 15, 2014 10:33 am | News | Comments

Building on a successful three-year pilot project...

Our Microbes Are a Rich Source of Drugs

September 11, 2014 3:08 pm | News | Comments

Bacteria that normally live in and upon us have...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Compound Protects Brain Cells After TBI

September 11, 2014 3:03 pm | News | Comments

A new class of compounds has now been shown to protect brain cells from the type of damage caused by blast-mediated traumatic brain injury (TBI). Read more...                           

Two Anti-Ebola Vaccines in Historic Race

September 11, 2014 2:41 pm | by Cynthia Fox, Science Editor | Articles | Comments

One of the most rapidly fast-tracked vaccines in history— an anti-Ebola “ChAd3” vaccine— just started clinical trial in humans, and may be done as soon as November. But a second fast-tracked anti-Ebola vaccine— called an “rVSV” vaccine— is hot on its heels. Read more...

CRUK, Asterias Biotherapeutics Partner on Lung Cancer Vaccine Trial

September 11, 2014 10:51 am | News | Comments

Cancer Research UK and Cancer Research Technology have reached an agreement with Asterias Biotherapeutics Inc. to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. Read more...

Advertisement

7 U.S.-Based Researchers Share $1.3M Eyesight Prize

September 11, 2014 10:37 am | News | Comments

Seven U.S.-based researchers are sharing a prize of 1 million euro ($1.3 million) from a Portuguese foundation for their work developing treatment for angiogenic diseases of the retina, the leading cause of blindness in the developed world. Read more...

MabVax Therapeutics, MSK Partner to Develop Anti-Cancer Therapies

September 10, 2014 2:17 pm | News | Comments

MabVax Therapeutics Holdings Inc. announced it has entered into agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences. Read more...

EMD Serono, Accelerated Cure Project Launch MS Research Program

September 10, 2014 2:09 pm | News | Comments

EMD Serono, Inc. and the Accelerated Cure Project for Multiple Sclerosis announced a lead founding sponsor agreement to help launch the Optimizing Treatment—Understanding Progression (OPT-UP) study. Read more...            

Blocking One Receptor on Cells Could Halt RA

September 10, 2014 2:00 pm | News | Comments

Researchers have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis. Read more...                          

Kinex Completes Acquisition of QuaDPharma

September 9, 2014 3:09 pm | News | Comments

Kinex Pharmaceuticals Inc. announced that it has completed the acquisition of QuaDPharma LLC, a Western New York based privately-held company specializing in pharmaceutical manufacturing, analytical and support services to the pharmaceutical and biotech industries. Read more...

Advertisement

Galena Begins Phase 2 GALE-401 Trial

September 9, 2014 3:04 pm | News | Comments

Galena Biopharma Inc. announced the first patient has been dosed in the GALE-401, or Anagrelide Controlled Release (CR), Phase 2 clinical trial, which will treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs). Read more...

Pharmatech, Weill Cornell Medical College Form Oncology Collaboration

September 9, 2014 2:58 pm | News | Comments

Pharmatech, Weill Cornell Medical College (WCMC) and 25 other leading oncology practices have agreed to evaluate an innovative program for rapidly identifying and enrolling patients in oncology clinical trials. Read more...        

NIAAA Conducting Trial of New Medication for Alcohol Use Disorder

September 9, 2014 2:46 pm | News | Comments

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) will conduct a clinical trial of gabapentin enacarbil as a potential treatment for alcohol use disorder (AUD). NIAAA estimates that the six-month trial will begin in the first half of 2015 and will enroll approximately 350 participants. Read more...    

Researchers ID New Genetic Target for a Different Kind of Cancer Drug

September 9, 2014 11:13 am | News | Comments

Researchers have discovered that the protein RBM4, a molecule crucial to the process of gene splicing, is drastically decreased in multiple forms of human cancer, including lung and breast cancers. Read more...            

New Extractor Optimized for Processing Medicinal Marijuana

September 9, 2014 9:30 am | by Dr. Kenneth James, Supercritical Fluid Technologies, Inc. | Articles | Comments

The need for pharmaceutical grade cannabis oil has increased as researchers continue to investigate its use for the treatment of various ailments such as muscle spasms, glaucoma, nausea, mood and behavioral disorders, sleep disorders and chronic pain. Read more...

Advertisement

Gilead, GSK Combo Drug Promising as PAH Treatment

September 8, 2014 3:14 pm | News | Comments

Gilead Sciences Inc. announced results from the AMBITION study, which was conducted in collaboration with GlaxoSmithKline (GSK). Read more...                                

Scientists Reveal Cell Secret Potentially Useful for Vaccines

September 8, 2014 3:00 pm | News | Comments

The best defense is a good offense, especially when it comes to the immune system. The troops that respond to an infection are split into two squadrons, and, until recently, it seemed that the two were independent, without much interaction. Read more...

Mayo Clinic, IBM Task Watson to Improve Clinical Trials

September 8, 2014 2:50 pm | News | Comments

Mayo Clinic and IBM announced plans to pilot Watson, the IBM cognitive computer, to match patients more quickly with appropriate clinical trials, beginning with research studies in cancer. Read more...              

Parkinson's, Cancer Findings Earn Medical Prizes

September 8, 2014 1:30 pm | by Malcolm Ritter, AP Science Writer | News | Comments

Key discoveries about breast cancer, Parkinson's disease and the body's handling of defective proteins have earned prestigious medical awards for five scientists. Read more...                     

J&J, Janssen Partner with University of Toronto on Brain Treatments

September 8, 2014 11:16 am | News | Comments

The University of Toronto announced a new strategic open innovation collaboration with Janssen Inc. facilitated by the Johnson & Johnson Innovation center of California that will support research through the Collaborative Center for Drug Research (CCDR). Read more...

AZ's COPD Drug Gets Mixed Results in Phase 2a

September 8, 2014 11:11 am | News | Comments

AstraZeneca announced that a Phase 2a study evaluating its novel investigational monoclonal antibody benralizumab in patients with COPD did not meet the primary endpoint, but that benralizumab demonstrated clinically significant improvements in lung function in the overall population. Read more...

Ascendia Advances Nano-Emulsion Technology Platform with ASD-002 Program

September 5, 2014 3:06 pm | News | Comments

Ascendia Pharmaceuticals announced that the company has successfully applied its nano-emulsion technology platform to a novel injectable formulation of clopidogrel- the world’s top-selling blood thinner medicine. Read more...       

Soligenix Acquires Phase-3-Ready Oncology Program

September 5, 2014 2:58 pm | News | Comments

Soligenix Inc. announced the acquisition of a novel orphan drug candidate, known as SGX301, which is poised to enter pivotal Phase 3 clinical testing for the treatment of cutaneous T-cell lymphoma and is highly synergistic with the company’s existing development pipeline. Read more...

NeuroDerm Starts Phase 2a Study of Parkinson’s Drug

September 5, 2014 11:11 am | News | Comments

NeuroDerm Ltd. announced that the first patients with severe Parkinson’s disease have been enrolled and dosed in a Phase 2a trial of ND0612H, a high-dose form of NeuroDerm’s proprietary liquid levodopa/carbidopa (LD/CD) drug formulation. Read more...

HIV Antibody Binds to Novel Target on Virus

September 4, 2014 2:46 pm | News | Comments

A team of scientists has discovered a new vulnerability in the armor of HIV that a vaccine, other preventive regimen or treatment, could exploit. Read more...                           

Google's Health Startup Forges Venture with AbbVie

September 4, 2014 2:34 pm | News | Comments

Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's. Read more...          

How Outsourcing Can Accelerate the Drug Development Process

September 4, 2014 10:36 am | by Matthew Weinberg, CEO, The Weinberg Group | Articles | Comments

Outsourcing is an old concept in the healthcare industry that has recently been applied to a new area: regulatory affairs. Traditionally conducted in-house, regulatory affairs is extremely critical to a product’s success. For certain companies, this entire function can and should be outsourced in its entirety, not just for discrete projects. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading